

## Seng Chin Mah– Education and Professional Qualifications



Year	Institution	Degree
1987	University of Basel	PhD, Biochemistry
1984	University of London	BSc (Hons), Pharmacology

Dr Seng Chin Mah possesses more than three decades of leadership experience in the pharmaceutical and biotechnology industries, particularly in the fields of development, regulatory affairs, and corporate management. He is currently Chairman of the Board of Directors at BioVersys AG and a board member at OSR Holdings Inc., both of which successfully went public in February 2025. Dr Mah has held executive positions in both publicly listed and private companies, including as CEO of Canyon Pharmaceuticals Group AG, where he was responsible for a comprehensive corporate restructuring and led the successful market launch of industry-recognised products.

Prior to his role at Canyon Pharmaceuticals, Dr Mah held international leadership positions at Novartis and Ciba, including Head of Clinical Safety & Epidemiology, Head of Drug Regulatory Affairs Europe, and Head of Development during the integration of Chiron. As a member of the Novartis Corporate Executive Group and the Board of Novartis Europharm Ltd, he initiated and led global transformation programmes, oversaw the regulatory approval of significant products such as Diovan, and made substantial contributions to clinical quality and regulatory strategies. His strategic perspective, technical expertise, and board-level experience make him a valuable asset to the organisations with which he collaborates.

### Key Competencies

- Extensive leadership experience at executive level in both public and private companies in the biotech and pharmaceutical industries
- Senior roles on the boards of companies listed on SIX (BioVersys AG) and NASDAQ, with in-depth knowledge of corporate governance
- Proven expertise in late-stage clinical development, regulatory strategies, and global product approvals
- Solid experience in strategic integration and transformation within international corporations, for example at Novartis–Chiron
- Successful development of two biotech companies up to their stock market listing
- Outstanding achievements in product differentiation and innovation, evidenced by the Frost & Sullivan Award for the Iprivask™ launch
- Experience in leading cross-functional and multicultural teams, as well as in talent development within demanding global structures